BioStock: BMS CAR T-cell approval - Elicera sees an opening

CAR T-cell therapies have shown transformational potential for the treatment liquid tumours. The recent approval of Bristol Myers Squibb’ multiple myeloma CAR T drug Abecma brings the number of CAR T therapy approvals up to five, with three coming during the last year alone. However, despite the remarkable innovation and excitement surrounding this technology, major challenges still remain, especially with regard to solid tumour treatments. Swedish gene therapy company Elicera may have what it takes to get past these hurdles.

Read the full article at biostock.se:

https://www.biostock.se/en/bms-car-t-cell-approval-elicera-sees-an-opening/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se